Posted by Michael Wonder on 15 Mar 2022
Prolonged price negotiation for Kymriah devastates leukaemia patients
15 March 2022 - Drained by dragging price negotiations between Novartis and the Government for breakthrough cancer treatment Kymriah (tisagenlecleucel), leukemia patients are voicing swift insurance coverage.
Kymriah, a chimeric antigen receptor T cell therapy for leukaemia and lymphoma, is an ultra-expensive drug costing over 500 million won ($402,694) per treatment that shows a therapeutic effect with only one injection.
